Boehringer Ingelheim joins hands with viratherapeutics to strengthen the immunotherapy product line

"We are very pleased to be able to establish this new partnership with viratotherapeutics, one of the core investors of viratotherapeutics," said Dr Michel pairet, managing director of innovation business of the board of directors of bringer Ingelheim "Oncolytic cell virus is one of the most promising programs in the new treatment of cancer research, and the new one developed by viratotherapeutics Technology has great advantages over other technologies currently in the R & D stage The new cooperation between the two sides highlights the long-term attention paid by bringer Ingelheim to the cooperation and the company's determination to continuously expand the fast-growing immune tumor product line, and is committed to many next-generation checkpoint inhibitors, including therapeutic cancer vaccines " Oncolytic viral therapy is a cancer treatment that uses viruses to infect and break down cancer cells Its mechanism of action is to fight against tumor by releasing tumor antigens usually hidden in immune system cells and triggering immune response Compared with other oncolytic virus platforms currently under development, vsv-gp has a shorter replication time The oncolytic virus does not integrate into DNA and has been modified to avoid inflammation of the nervous system caused by wild-type viruses In vsv-gp, the glycoprotein of vesicular stomatitis virus is replaced by that of LCMV, which can hide the virus in the immune system In preclinical model, no virus neutralizing antibody was added, which made repeat operation possible "This will be an important milestone in the development of VirA therapeutics, and the entire team of the company has invested a lot of energy in our technology platform and leading candidate drugs In addition to the research and development of oncolytic cells, vsv-gp also demonstrated the ability to prepare and promote the anti-cancer immune response, while not triggering an effective anti-virus immune response These characteristics will create conditions for the breakthrough application of this new technology With the support of Brigitte Ingelheim, we can go all out to study this platform and the potential of our vsv-gp oncolytic therapy for treatment " Professor Dr dorotheevon laer, founder and CEO of viratotherapeutics science, said, "we will continue to study the potential of vsv-gp, with the help of therapeutic genes and antigens, to study its application in preventive or therapeutic vaccine vectors." With a long-term perspective, bringer Ingelheim focuses on cutting-edge science, creating a stable environment for the company to develop next-generation medical breakthrough products This new project will become another important development cornerstone of the company's long-term strategy, striving to improve the quality of life of patients with a large number of unmet treatment needs The driving force of research on the cancer business of Brigitte Ingelheim comes from the company's determination to promote clinical treatment time and improve the quality of life of patients struggling with cancer Through our independent scientific innovation and cooperation, we focus on finding and providing the most advanced breakthrough cancer treatment drugs to meet the needs of patients, nursing staff and healthcare professionals We have a clear strategic plan to become a leader in lung cancer treatment Boehringer Ingelheim has successfully launched two products for the treatment of NSCLC, which have been widely used and become valuable products in clinical practice Long term insight and learning in the field of research and development is an important element of innovation, and also an important premise for us to promote clinical practice in the field of lung cancer and other types of cancer in the future Bringer Ingelheim is one of the top 20 pharmaceutical companies in the world Headquartered in Ingelheim, Germany Bringer Ingelheim has 145 subsidiaries around the world, with a total staff of more than 47500 As a family business founded in 1885, Boehringer Ingelheim is committed to the research, development, production and marketing of products with high therapeutic value for human and veterinary drugs In Boehringer Ingelheim, social responsibility is an important part of corporate culture, including our participation in social projects on a global scale, such as "create more health" activities, but also the care of employees Respect, equal opportunities and a balanced career and family model are the basis for mutual cooperation The company also attaches great importance to environmental protection and sustainability in all aspects About ViraTherapeutics GmbH ViraTherapeutics GmbH (ViraT), located in Austria, is a privately owned biopharmaceutical company The company develops promising innovative cancer treatment methods and conducts immunotherapy research with virus as the carrier Virat was founded in 2013 as a spin off of the University by Dr dorotheevon laer, head of Virology at the University of Innsbruck Virat develops a oncolytic cancer vaccine through a chimeric virus isolated from vesicular stomatitis virus (VSV), so it is called vsv-gp for short At first, virat obtained pre seed financing from cast (Center for academic spin off tyre), tyre and Austria wirtschaftsservice GmbH (AWS – Austrian government promotion bank) Virat is funded by the Biringer Ingelheim venture capital fund (bIVF), EMBL ventures and empl foundation The funding institutions include AWS, which invests through its venture capital plan and seed financing plan, and FFG, which invests through several projects, currently has 14 employees Virat won the best of biotechnology international business plan competition in 2012, and won the second place in the science 4 life venture capital cup competition in 2013 Virat has a partnership with Innsbruck Medical University and some scientists in Professor von laer's laboratory serve virat About EMBL ventures EMBL ventures is an independent venture capital institution, which currently manages three funds with a total assets of 120 million euros on behalf of major European institutions and private investors The fund adopts a positive investment strategy and currently invests in 15 companies The main investment area of EMBL ventures is life science, and its investment activities are carried out by making full use of its good relationship with the European Molecular Biology Laboratory (EMBL) and its technology transfer organization, EMBL enterprise management technology transfer GmbH EMBL ventures' professionals pursue practical investment methods, assist some companies with disruptive technologies to set up and finance in an entrepreneurial start-up environment, and finally carry out equity transactions with a strategic partner seeking to acquire external product innovation About biringelheim venture capital fund biringelheim venture capital fund (bIVF) was founded in March 2010 The investment direction is biotechnology and start-up companies, aiming to promote innovation and development in the field of medical science Investment is mainly focused on but not limited to immune regulation, especially immune tumor, tissue regeneration, new treatment methods, such as gene therapy, cell therapy, ADC and microbial therapy This reflects bIVF's concern for platform technology, with an eye to expanding the current treatment field focus of Boehringer Ingelheim (BI), demonstrates bIVF's long-term emphasis on research of new treatment methods and technologies, goes beyond the current planning of Boehringer Ingelheim, and is committed to the potential well-being of patients in the future Biff plays a key role in its portfolio companies - creating significant added value through its extensive experience in drug development, science and management expertise BIVF currently manages 100 million euros of assets and manages and oversees a portfolio of 17 dynamic companies.